171 related articles for article (PubMed ID: 38348830)
1. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
Dubé K; Ndukwe SO; Korolkova A; Dee L; Sugarman J; Sauceda JA
HIV Res Clin Pract; 2024 Jan; 25(1):2312318. PubMed ID: 38348830
[TBL] [Abstract][Full Text] [Related]
2. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.
Bilger A; Plenn E; Barg FK; Rendle KA; Carter WB; Lamour-Harrington A; Jones N; Peterson B; Sauceda JA; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dubé K
HIV Res Clin Pract; 2023 Oct; 24(1):2267825. PubMed ID: 37837376
[TBL] [Abstract][Full Text] [Related]
3. "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption.
Neergaard R; Jones NL; Roebuck C; Rendle KA; Barbati Z; Peterson B; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dube K; Barg FK
AIDS Res Hum Retroviruses; 2023 Aug; 39(8):414-421. PubMed ID: 35979886
[TBL] [Abstract][Full Text] [Related]
4. "It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States.
Campbell DM; Dubé K; Cowlings PD; Dionicio P; Tam RM; Agarwal H; Stockman JK; Auerbach JD; Sauceda JA; Conroy AA; Johnson MO
BMC Public Health; 2022 Jul; 22(1):1317. PubMed ID: 35810288
[TBL] [Abstract][Full Text] [Related]
5. Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.
Lee MJ; Godakandaarachchi P; Collins S; Racz M; Sharp A; Fidler S; Fox J
J Virus Erad; 2023 Dec; 9(4):100360. PubMed ID: 38188642
[TBL] [Abstract][Full Text] [Related]
6. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.
Dubé K; Kanazawa J; Campbell C; Boone CA; Maragh-Bass AC; Campbell DM; Agosto-Rosario M; Stockman JK; Diallo DD; Poteat T; Johnson M; Saberi P; Sauceda JA
AIDS Res Hum Retroviruses; 2022 Jan; 38(1):50-63. PubMed ID: 33947268
[TBL] [Abstract][Full Text] [Related]
7. Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions.
Dubé K; Agarwal H; Carter WB; Dee L; Taylor J; Roebuck C; Peterson B; Patel H; Ndukwe S; Lynn KM; Lalley-Chareczko L; Hiserodt E; Kim S; Rosenbloom D; Evans BR; Anderson M; Hazuda DJ; Bateman K; Howell BJ; Azzoni L; Mounzer K; Tebas P; Montaner LJ
HIV Res Clin Pract; 2022 Aug; 23(1):76-90. PubMed ID: 35968737
[No Abstract] [Full Text] [Related]
8. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
Dubé K; Kanazawa J; Dee L; Taylor J; Campbell DM; Brown B; Johnson MO; Saberi P; Sauceda JA; Sugarman J; Peluso MJ
HIV Res Clin Pract; 2021 Feb; 22(1):14-30. PubMed ID: 33757411
[No Abstract] [Full Text] [Related]
9. Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.
Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):260-267. PubMed ID: 31608648
[TBL] [Abstract][Full Text] [Related]
10. Motivations, barriers and experiences of participants in an HIV reservoir trial.
De Scheerder MA; van Bilsen WPH; Dullaers M; Martinez-Picado J; Davidovich U; Vandekerckhove L
J Virus Erad; 2021 Mar; 7(1):100029. PubMed ID: 33598311
[TBL] [Abstract][Full Text] [Related]
11. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
Lee MJ; Collins S; Babalis D; Johnson N; Falaschetti E; Prevost AT; Ashraf A; Jacob M; Cole T; Hurley L; Pace M; Ogbe A; Khan M; Zacharopoulou P; Brown H; Sutherland E; Box H; Fox J; Deeks S; Horowitz J; Nussenzweig MC; Caskey M; Frater J; Fidler S
Trials; 2022 Apr; 23(1):263. PubMed ID: 35382844
[TBL] [Abstract][Full Text] [Related]
12. HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.
Okumu EA; Henderson GE; Golin C; Kuczynski K; Ormsby NQ; Peay HL
J Virus Erad; 2023 Jun; 9(2):100331. PubMed ID: 37416088
[TBL] [Abstract][Full Text] [Related]
13. A partner protection package for HIV cure-related trials involving analytical treatment interruptions.
Dubé K; Morton T; Fox L; Dee L; Palm D; Villa TJ; Freshwater W; Taylor J; Graham G; Carter WB; Sauceda JA; Peluso MJ; Rid A
Lancet Infect Dis; 2023 Oct; 23(10):e418-e430. PubMed ID: 37295453
[TBL] [Abstract][Full Text] [Related]
14. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
Hellmuth J; Muccini C; Colby DJ; Kroon E; de Souza M; Crowell TA; Chan P; Sacdalan C; Intasan J; Benjapornpong K; Tipsuk S; Puttamaswin S; Chomchey N; Valcour V; Sarnecki M; Tomaka F; Krebs SJ; Slike BM; Jagodzinski LL; Dumrongpisutikul N; Sailasuta N; Samboju V; Michael NL; Robb ML; Vasan S; Ananworanich J; Phanuphak P; Phanuphak N; Paul R; Spudich S
Clin Infect Dis; 2021 Oct; 73(7):e1885-e1892. PubMed ID: 32916708
[TBL] [Abstract][Full Text] [Related]
15. 'With this study, we have hope that something is coming': community members' perceptions of HIV cure-related research in Durban, South Africa - a qualitative focus group study.
Dubé K; Mthimkhulu D; Ngcobo W; Mindry D; Maphalala L; Pillay V; Tran W; Korolkova A; Ndung'u T; Dong K
HIV Res Clin Pract; 2023 Jul; 24(1):2243046. PubMed ID: 37555592
[TBL] [Abstract][Full Text] [Related]
16. Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection.
van Paassen P; Dijkstra M; Peay HL; Rokx C; Verbon A; Reiss P; Prins JM; Henderson GE; Rennie S; Nieuwkerk PT; de Bree GJ
J Virus Erad; 2022 Jun; 8(2):100072. PubMed ID: 35769632
[TBL] [Abstract][Full Text] [Related]
17. Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.
De Scheerder MA; Van Hecke C; Zetterberg H; Fuchs D; De Langhe N; Rutsaert S; Vrancken B; Trypsteen W; Noppe Y; Van Der Gucht B; Pelgrom J; Van Wanzeele F; Palmer S; Lemey P; Gisslén M; Vandekerckhove L
J Antimicrob Chemother; 2020 May; 75(5):1311-1320. PubMed ID: 32053203
[TBL] [Abstract][Full Text] [Related]
18. Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.
Lau JSY; Cromer D; Pinkevych M; Lewin SR; Rasmussen TA; McMahon JH; Davenport MP
J Infect Dis; 2022 Aug; 226(2):236-245. PubMed ID: 35104873
[TBL] [Abstract][Full Text] [Related]
19. Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies.
Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
AIDS Res Ther; 2020 Nov; 17(1):65. PubMed ID: 33168019
[TBL] [Abstract][Full Text] [Related]
20. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.
Strongin Z; Sharaf R; VanBelzen DJ; Jacobson JM; Connick E; Volberding P; Skiest DJ; Gandhi RT; Kuritzkes DR; O'Doherty U; Li JZ
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
